Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for Parkinson’s disease driven by hyperactive LRRK2. Neuron23 combines advances in human genetics with a state-of-the-art drug discovery and biomarker platform, leveraging advanced techniques in machine learning and artificial intelligence to advance therapeutics aimed at impacting disease progression. The company’s focus is on transforming the future of treatment for PD through innovation, collaboration, and dedication to enhancing patient outcomes. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.
| Website | https://neuron23.com |
| Employees | 34 (34 on RocketReach) |
| Founded | 2018 |
| Address | 343 Oyster Point Blvd Suite 120, South San Francisco, California 94080, US |
| Industry | Biotechnology Research |
| Keywords | Precision Medicine, Genetic Diseases, Biotechnology, Clinical Stage, Drug Development, Human Genetics, Gene Therapy, Rare Diseases, Pharmaceutical Research, Biopharma, Therapeutics, Clinical Trials, Drug Discovery, Medical Research, Health Technology, Biomedical Research, Life Sciences, Personalized Medicine |
| Competitors | Amgen, AstraZeneca, Novartis, Vertex Pharmaceuticals, Genentech, Sanofi, Biogen, Regeneron, Sage Therapeutics, Lilly India +37 more (view full list) |
Looking for a particular Neuron23 employee's phone or email?
Arash Rassoulpour is the COO of Neuron23.
34 people are employed at Neuron23.
Neuron23 is based in South San Francisco, California.